Navigation Links
The Leukemia & Lymphoma Society Announces Appointment of New President and CEO
Date:4/10/2008

John Walter, with LLS Since 1995, Tapped to Steer the World's Largest

Organization Dedicated to Blood Cancer Research and Patient Services

WHITE PLAINS, N.Y., April 10 /PRNewswire/ -- The Leukemia & Lymphoma Society has appointed John Walter as its president and chief executive officer, with the task of leading the world's largest organization dedicated to funding blood cancer research as it strives to find cures and prolong and enhance the lives of patients with leukemia, lymphoma and myeloma.

(Photo: http://www.newscom.com/cgi-bin/prnh/20080410/NYTH074 )

Walter, who has been with LLS since 1995, most recently as chief operating officer, succeeds Dwayne Howell, Ph.D., who retired in February.

"After conducting a nationwide search, the LLS Board of Directors agreed that John Walter was the best candidate to steer us as we move toward achieving our mission of curing blood cancers and improving the lives of patients and their families," said LLS Chairman David Frantze. "The Leukemia & Lymphoma Society is a $300 million plus organization committed to identifying the best scientists in the world in the field of blood cancer research and providing the funding to help them find cures and better therapies. In John, we have somebody at the helm with the vision and leadership qualities to provide support for our patients in their journey dealing with these devastating diseases."

Walter started his career at LLS as senior vice president of finance and information technology, during which time he enhanced the efficiencies and internal controls of the organization by centralizing all finance and treasury operations in the United States and Canada. He also established LLS's information technology and Web functions.

He served as chief financial officer, and then, as executive vice president, strategic alliances and new business development he designed and implemented LLS's Co-Pay Assistance Program, a service that helps blood cancer patients with their health insurance premiums and prescription drug co-pays.

He came to LLS from the March of Dimes, where he worked for nine years. He had previously worked at Donaldson, Lufkin & Jenrette and at Bristol-Myers Squibb, where he had broad international experience.

About The Leukemia & Lymphoma Society

The Leukemia & Lymphoma Society(R), headquartered in White Plains, NY, with 68 chapters in the United States and Canada, is the world's largest voluntary health organization dedicated to funding blood cancer research and providing education and patient services. The LLS mission: Cure leukemia, lymphoma, Hodgkin's disease and myeloma, and improve the quality of life of patients and their families. Since its founding in 1949, LLS has invested more than $550 million in research specifically targeting leukemia, lymphoma and myeloma. Last year alone, LLS made 5.1 million contacts with patients, caregivers and healthcare professionals.

For more information about blood cancer, visit http://www.LLS.org or call the LLS Information Resource Center (IRC), a call center staffed by master's level social workers, nurses and health educators who provide information, support and resources to patients and their families and caregivers. IRC information specialists are available at (800) 955-4572, Monday through Friday, 9 a.m. to 6 p.m. ET.

Contact: Andrea Greif

914.821.8958

andrea.greif@lls.org


'/>"/>
SOURCE The Leukemia & Lymphoma Society
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. The Leukemia & Lymphoma Society Hosts Workshop On Weighing Treatment Options For Chronic Myelogenous Leukemia
2. Study finds heart failure is rare among leukemia patients on imatinib
3. Altered expression of ultraconserved noncoding RNAs linked to human leukemias and carcinomas
4. Cephalon Submits New Drug Application for TREANDA for the Treatment of Chronic Lymphocytic Leukemia
5. FDA Approves Expanded Labeling for Campath(R) to Include First-line Treatment for Leading Form of Adult Leukemia
6. Novel strategy under study for aggressive leukemia
7. Drug has ability to cure type of leukemia
8. The Leukemia & Lymphoma Society Provides Patients with the Latest Information on Myeloma
9. Micromet Receives Regulatory Approval to Conduct a Phase 2 Clinical Trial Investigating MT103 (MEDI-538) in Patients with Acute Lymphoblastic Leukemia
10. Video and Photo: Tasigna(R) Receives US Approval Providing New Hope to Chronic Myeloid Leukemia Patients With Resistance or Intolerance to Existing Therapies
11. St. Jude Finds Anti-Leukemia Drug Increases Patient Fatigue
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/23/2017)... ... March 23, 2017 , ... The TouchPoint Solution, home of ... manage stress and anxiety. , “Buzzies change the way we interact with stress ... Buzzies. , Since its launch date in December 2016, The TouchPoint Solution has sold ...
(Date:3/23/2017)... CA (PRWEB) , ... March 23, 2017 , ... ... management and workflow solutions, today named The Resource Group as their 2016 Microsoft ... and partner conference in Newport Beach, CA. The award recognizes The Resource ...
(Date:3/23/2017)... ... 23, 2017 , ... According to the National Sleep Foundation , poor ... the only cause of the sunken-eye look, which can include dark circles or bags ... poor health are likely due to genetics, dehydration, allergies, and losing fat beneath the ...
(Date:3/23/2017)... CA (PRWEB) , ... March 23, 2017 , ... ... FACIS Monthly Monitoring Healthcare products at competitive pricing. Verisys through ... sanctions, Exclusions, Debarments, License restrictions and Disciplinary actions. , “We are delighted to ...
(Date:3/23/2017)... ... March 23, 2017 , ... On 2 March ... the US Special Operations Command’s Patriot Award. The award was presented by the ... Force Dagger Foundation for its significant and enduring support to the command. ...
Breaking Medicine News(10 mins):
(Date:3/23/2017)... 23, 2017   Icertis , the leading ... the cloud, today announced an upgrade to the ... to improve clinical trials contract management. Built on ... the solution speeds up clinical trial contracting while ... (CRO). "The pharmaceutical industry is ...
(Date:3/23/2017)... 23, 2017  Interpace Diagnostics Group, Inc. (NASDAQ: ... integrated commercial company that provides clinically useful molecular ... it has entered into agreements to successfully restructure ... ("RedPath") and concurrently terminate its royalty and milestone ... debt to RedPath amounting to $9.34 million is ...
(Date:3/23/2017)... 2017  Additive Orthopaedics, LLC., an early stage ... kicked off a multi-centered clinical study to measure ... According to Brian McLaughlin , ... structures have already shown tremendous post-operative success and ... wedges from which we have seen evidence of ...
Breaking Medicine Technology: